**OriGene Technologies, Inc.**
9620 Medical Center Drive, Ste 200
Rockville, MD 20850, US
Phone: +1-888-267-4436
https://www.origene.com
techsupport@origene.com
EU: info-de@origene.com
CN: techsupport@origene.cn

# Product datasheet for RC204120L2V

## MOCOS (NM_017947) Human Tagged ORF Clone Lentiviral Particle

### Product data:

| | |
|---|---|
| **Product Type:** | Lentiviral Particles |
| **Product Name:** | MOCOS (NM_017947) Human Tagged ORF Clone Lentiviral Particle |
| **Symbol:** | MOCOS |
| **Synonyms:** | HMCS; MCS; MOS |
| **Mammalian Cell Selection:** | None |
| **Vector:** | pLenti-C-mGFP (PS100071) |
| **Tag:** | mGFP |
| **ACCN:** | NM_017947 |
| **ORF Size:** | 2664 bp |
| **ORF Nucleotide Sequence:** | The ORF insert of this clone is exactly the same as(RC204120). |
| **OTI Disclaimer:** | The molecular sequence of this clone aligns with the gene accession number as a point of reference only. However, individual transcript sequences of the same gene can differ through naturally occurring variations (e.g. polymorphisms), each with its own valid existence. This clone is substantially in agreement with the reference, but a complete review of all prevailing variants is recommended prior to use. More info |
| **OTI Annotation:** | This clone was engineered to express the complete ORF with an expression tag. Expression varies depending on the nature of the gene. |
| **RefSeq:** | NM_017947.1 |
| **RefSeq Size:** | 2747 bp |
| **RefSeq ORF:** | 2667 bp |
| **Locus ID:** | 55034 |
| **UniProt ID:** | Q96EN8 |
| **Cytogenetics:** | 18q12.2 |
| **MW:** | 98.2 kDa |

View online »

**Gene Summary:** This gene encodes an enzyme that sulfurates the molybdenum cofactor which is required for activation of the xanthine dehydrogenase (XDH) and aldehyde oxidase (AO) enzymes. XDH catalyzes the conversion of hypoxanthine to uric acid via xanthine, as well as the conversion of allopurinol to oxypurinol, and pyrazinamide to 5-hydroxy pyrazinamide. Mutations in this gene cause the metabolic disorder classical xanthinuria type II which is characterized by the loss of XDH/XO and AO enzyme activity, decreased levels of uric acid in the urine, increased levels of xanthine and hypoxanthine in the serum and urine, formation of xanthine stones in the urinary tract, and myositis due to tissue deposition of xanthine. [provided by RefSeq, Apr 2017]